Physician profile
Charlene Locklear
NPI 1083875793
$6,361.35
in general payments reported to CMS, 2019-2025
42 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $500 · 2021: $784 · 2022: $986 · 2023: $1,349 · 2024: $1,149 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,525.04 | 2020-2025 | |
| Novo Nordisk INC | $1,364.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $717.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $364.07 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $177.84 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $171.71 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.64 | 2022-2025 | Caplyta |
| Allergan, INC. | $160.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $142.38 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $130.29 | 2024-2025 | Nuzyra, Xhance |
| Ironwood Pharmaceuticals, INC | $112.06 | 2021-2024 | Linzess |
| Mylan Specialty L.P. | $99.91 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.06 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $91.83 | 2021-2025 | |
| Pfizer INC. | $90.39 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.